Sanofi to Acquire Bioverativ for $11.6 Billion
January 22 2018 - 1:01AM
Dow Jones News
By Marc Bisbal Arias
Sanofi SA (SAN.FR) said Monday that it will acquire all
outstanding shares in Bioverativ Inc. (BIVV) for $11.6 billion to
expand its presence in specialty care and strengthening leadership
in rare diseases.
The operation is expected to close within three months, Sanofi
said.
The French company said that it will pay $105 in cash for each
share. This price represents a 64% premium to Bioverativ's closing
price on Jan. 19, the company said.
U.S.-based Bioverativ, which generated $847 million in sales in
2016, is a biopharmaceutical company focused on therapies for
hemophilia and other rare blood disorders, Sanofi said.
"With Bioverativ, a leader in the growing hemophilia market,
Sanofi enhances its presence in specialty care and leadership in
rare diseases, in line with its 2020 roadmap, and creates a
platform for growth in other rare blood disorders," Chief Executive
Olivier Brandicourt said.
Sanofi expects the deal to be immediately accretive to its
earnings per share in 2018 and up to 5% accretive in 2019. It also
forecasts it will achieve return on invested capital in excess of
cost of capital within three years.
"Sanofi brings proven capabilities and a global infrastructure,
which we believe will help to more rapidly expand access to our
medicines globally and further our mission of transforming the
lives of people with rare blood disorders," Bioverativ's Chief
Executive John Cox said.
Hemophilia represents the largest market for rare diseases,
Sanofi said, with close to $10 billion in annual sales and 181,000
people affected worldwide.
The market is expected to grow more than 7% per year through
2022 is expected.
Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com
(END) Dow Jones Newswires
January 22, 2018 01:46 ET (06:46 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.